Trevi Therapeutics (TRVI) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 3, 2026, with voting available online or virtually until June 2, 2026.

• Key proposals include director election, auditor ratification, executive compensation, stock plan amendment, and share authorization increase.

Voting matters and shareholder proposals

• Election of one Class I director, Michael Heffernan, to serve until the 2029 annual meeting.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory approval of executive compensation for named executive officers.

• Approval of the Amended and Restated 2019 Stock Incentive Plan.

• Approval to amend the certificate of incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares.

• Provision for transaction of other business properly brought before the meeting.

Board of directors and corporate governance

• Board recommends all proposals, including the election of Michael Heffernan as Class I director.